Instil Bio
TILInstil Bio is a clinical-stage biotechnology company primarily focused on the acquisition, in-licensing, and development of novel therapeutic candidates for diseases with significant unmet medical needs.
Table of contents
Earnings
Next report
Aug 12, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Instil Bio is a clinical-stage biotechnology company primarily focused on the acquisition, in-licensing, and development of novel therapeutic candidates for diseases with significant unmet medical needs. Following the discontinuation of its lead bispecific antibody program in early 2026, the company has shifted its strategy toward identifying new innovative assets while maintaining a legacy interest in cell therapy technologies. Additionally, the company generates value through the ownership and leasing of specialized clinical and commercial manufacturing facilities.
The company is currently in a transitional phase, pivoting from failed lead programs to an acquisition-focused strategy while competing against well-capitalized major pharmaceutical entities for novel assets.
Questions, answered.
- What is Instil Bio's market cap?
- Instil Bio (TIL) has a market capitalization of $51.9M and trades on NASDAQ.
- Who are Instil Bio's competitors?
- Instil Bio's key competitors include Iovance Biotherapeutics, AstraZeneca, Immuneering Corporation Class A Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Instil Bio partner with?
- Instil Bio's notable partners include ImmuneOnco Biopharmaceuticals (Shanghai) Inc..
- What subsidiaries does Instil Bio have?
- Instil Bio's subsidiaries include Axion Bio, Inc., Complex Therapeutics LLC.
- Where is Instil Bio headquartered?
- Instil Bio is headquartered in United States of America and employs approximately 49 people. It has been publicly traded since 2021.